Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 19/20 | 0.76 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604773 | 1.00 | HRH4 (0.76) | HRH4HRH3KCNH2 | |
| SCHEMBL604835 | 1.00 | HRH4 (0.76) | HRH4HRH3KCNH2 | |
| SCHEMBL604565 | 0.90 | HRH3 (0.73) | HRH4HRH3 | |
| SCHEMBL604364 | 0.89 | HRH4 (0.74) | HRH4HRH3KCNH2 | |
| SCHEMBL604365 | 0.89 | HRH4 (0.74) | HRH4HRH3KCNH2 | |
| SCHEMBL12268391 | 0.88 | HRH4 (0.76) | HRH4HRH3KCNH2 | |
| SCHEMBL607144 | 0.87 | HRH4 (0.71) | HRH4HRH3KCNH2 | |
| SCHEMBL603422 | 0.87 | HRH4 (0.71) | HRH4HRH3KCNH2 | |
| SCHEMBL602267 | 0.87 | HRH4 (0.71) | HRH4HRH3KCNH2 | |
| SCHEMBL602456 | 0.87 | HRH4 (0.71) | HRH4HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2599386-A1 | 2-aminopyrimidine modulators of the histamine h4 receptor | Janssen Pharmaceutica N.V. (BE) | 2013-06-05 | — | — | EP | claimed |
| US-20110218338-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janseen Pharmaceutiacal NV | 2011-09-08 | — | — | US | claimed |
| WO-2009077608-A1 | 2 -AMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 ANTAGONISTS | PALAU PHARMA, S. A. (ES) | 2009-06-25 | — | — | WO | claimed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-20150176010-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2015-06-25 | — | — | US | disclosed |
| US-7923451-B2 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-12 | — | — | US | disclosed |
| US-7923451-B2 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-12 | — | — | US | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| WO-2009077608-A1 | 2 -AMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 ANTAGONISTS | PALAU PHARMA, S. A. (ES) | 2009-06-25 | — | — | WO | disclosed |
| WO-2008100565-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218338-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH2, HRH3 | HRH4 1/4885HRH3 3/4885KCNH2 926/4885 |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | HRH4, HRH2, HRH3 | HRH4 1/4885HRH3 3/4885KCNH2 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.